TOPICS
Sales Enablement for Biotech & Pharma
DIRECT ANSWER
Sales enablement is the process of equipping sales teams with the content, training, tools, and data they need to engage buyers effectively at every stage of the sales cycle. Marketing's role is to produce and maintain the assets sales relies on — case studies, competitive battlecards, objection-handling guides, proposal templates — and ensure they are findable, current, and calibrated to actual buyer questions. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What sales enablement means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
What Marketing Owns in Sales Enablement
Marketing-owned enablement assets include: case studies and social proof organized by vertical and use case; competitive intelligence documents that give sales accurate, defensible responses to competitor comparisons; persona-specific pitch decks; and ROI calculators that quantify value in terms each buyer persona cares about. All of these should be version-controlled and tagged with the stage of the sales cycle they support.
Content governance is the persistent gap in most enablement programs. Sales teams report spending significant time searching for the right asset or, worse, using outdated versions because the repository is disorganized. Naming conventions, a clear taxonomy, and quarterly audits that archive stale content are unglamorous but essential infrastructure work.
Running sales enablement for Biotech & Pharma with CoMo
CoMo's agents apply sales enablement across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Sales Enablement for Biotech & Pharma — common questions
Who should own sales enablement — marketing, sales ops, or a dedicated function?
Ownership varies by company size. In companies under 50 sales reps, marketing typically owns content creation while sales ops owns the tooling and repository. Above 100 reps, a dedicated enablement function with its own headcount becomes cost-effective. Regardless of structure, marketing and sales leadership must jointly define the content roadmap.
How does sales enablement differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.